secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK:        0000879407
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001628280-25-038867
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025
-----------------------------------------------------------------------------

- Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).
- Cash & securities $900.4M; credit facility $240.3M; liability from royalty sale $360.3M.
- Sanofi to pay Visirna $130M upfront for Greater China license to plozasiran; up to $265M milestones.
- Earned $100M milestone from Sarepta; second enrollment target for ARO-DM1 may trigger $200M by end-2025.
- Plozasiran NDA accepted with PDUFA date Nov 18, 2025; Phase 3 SHASTA-3/4 and MUIR-3 fully enrolled.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/0001628280-25-038867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/arwr-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-038867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer